<DOC>
	<DOC>NCT02027389</DOC>
	<brief_summary>The objective of this study is to evaluate the impact of the Alere&amp;#8482; PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.</brief_summary>
	<brief_title>Impact of Rapid Detection of MRSA</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<criteria>Inclusion criteria: 1. Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures (both control and intervention periods) 2. Above, with rapid PBP2a testing (intervention period only). Exclusion criteria: 1. Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms in the culture). 2. Patients who have not provided MN authorization to use their medical records for research. 3. Patients who have had the FilmArray Blood culture identification diagnostic test performed on an index S. aureus blood culture. 4. Patients who have had a sterile source S. aureus culture within the prior 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MSSA, MRSA</keyword>
</DOC>